Genentech uses an extensive set of criteria, including scientific rationale and medical need, to determine which projects to move from discovery research into development. Our clinical scientists and medical professionals then perform the essential role of translating basic science into patient benefit. They help Genentech determine which potential new drugs are tested against specific diseases in the clinic and guide chosen drug candidates through the many phases of clinical testing.

View the newly combined Roche Group development pipeline. Our R&D activities are focused on applying excellent science to discover and develop new medicines with the potential to become first-in-class or best-in-class therapeutics. Combining Roche and Genentech has created one of the strongest R&D pipelines in the industry.

View Genentech's Early-stage development pipeline. Genentech Research and Early Development operates as an independent center within the Roche Group and currently has over 20 new molecular entities in early-stage clinical trials.

If you are having trouble viewing our pipeline in PDF or flash formats, or would like to view our pipeline by phase, click here.